000			03281cam a2200349 a 4500
003			EG-GiCUC
005			20250223031614.0
008			161115s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.11.29.Ph.D.2016.In.A
100	0		_aInas Anas Abdelmonem Harb
245	1	0	_a Assessment of lusitropic effect of phosphodiesterase -5 inhibitors and erythropoietin as new threaputic modality in treatment of diastolic heart failure in rats / _cInas Anas Abdelmonem Harb ; Supervised Soheir Ali Abdelwahed , Hisham Attia Awad , Essam Fouad Alalkamy
246	1	5	_aتقييم التأثير محفز الإنبساط لمجموعة مثبطات إنزيم فسفودايستيراذ 5والإيرثروبيوتين كبديل علاجي جديد لقصور القلب الإنبساطي في الجرذان
260			_aCairo : _bInas Anas Abdelmonem Harb , _c2016
300			_a151 , 11 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pharmacology
520			_aBackground: Despite advances in the management of heart failure, the prognosis of these patients remains poor. The results of the randomized clinical trials in patients with DHF (or HFPEF) have demonstrated that while neurohumoral antagonists such as beta blockers, angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are effective in treatment of systolic heart failure (SHF), they do not decrease morbidity and mortality in DHF (Redfield et al., 2003). Development of new forms of interventions remains a challenging task (Lloyd-Jones et al., 2010). Aim: The aim of this work is assessment of lusitropic effect of phosphodiesterase -5 inhibitors (sildenafil) and EPO in a model of diastolic heart failure in female albino rats induced by NG-nitro-L-arginine methyl ester (L-NAME). In addition, to assess the effect of the aforementioned drugs on left ventricle haemodynamic parameters and left ventricular remodeling. Results: In the present study treatment with L-NAME revealed, significant reduction in the mean LVEF and LVFS compared to that recorded in normal group . While milrinone, sildenafil, erythropoietin and combination treatment treated groups showed significant increase in the mean LVEF and LVFS compared to that recorded in L-NAME treated group. Regards ECG records, QT interval prolonged with L-NAME administration compared to that recorded in normal group. While treatment with milrinone , sildenafil and combination treatment showed significant shortening of QT interval compare to that recorded in L-NAME treated group. On the other hand , erythropoietin reduction of QT interval was non-significant compare to that recorded in L-NAME treatment
530			_aIssued also as CD
653		4	_a ECHO cardiography
653		4	_aDiastolic heart failure
653		4	_aSildenafil
700	0		_aEssam Fouad Alalkamy , _eSupervisor
700	0		_aHisham Attia Awad , _eSupervisor
700	0		_aSoheir Ali Abdelwahed , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSoheir _eCataloger
942			_2ddc _cTH
999			_c58635 _d58635